These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31422893)

  • 1. Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.
    Heng W; You C; Shangli C; Chuang Q; Mingzhe X
    Lung Cancer; 2019 Oct; 136():153-155. PubMed ID: 31422893
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
    Zhu YC; Du KQ; Wang WX; Song ZB; Xu CW; Chen G; Zhuang W; Lv TF; Song Y
    Lung Cancer; 2018 Jul; 121():101-104. PubMed ID: 29773459
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
    Xu L; Qi Q; Zhang Y; Cui J; Liu R; Li Y
    Lung Cancer; 2019 Jul; 133():23-31. PubMed ID: 31200823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
    Wang J; Chen J
    BMC Cancer; 2019 Feb; 19(1):131. PubMed ID: 30736738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
    Wu K; Guo C; Li R
    Medicine (Baltimore); 2019 May; 98(18):e15489. PubMed ID: 31045832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an
    Guan Y; Song Z; Li Y; Guo H; Shi J; Zhang X; Yao M
    Oncologist; 2019 Aug; 24(8):1027-1030. PubMed ID: 31064887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.
    Jin LL; Wu ZZ; Wang YL; Chen DS; Li S; Xiao M; Zhao X
    Invest New Drugs; 2021 Oct; 39(5):1419-1421. PubMed ID: 33835358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of icotinib in advanced lung squamous cell carcinoma.
    Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
    Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
    Li K; Zhou F; Zhou Y; Zhang S; Li Q; Li Z; Liu L; Wu G; Meng R
    Int J Mol Med; 2019 Aug; 44(2):437-446. PubMed ID: 31173177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
    Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
    Cancer Med; 2020 Jan; 9(1):12-18. PubMed ID: 31692291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing.
    Zhu YC; Wang WX; Li XL; Xu CW; Chen G; Zhuang W; Lv T; Song Y
    J Thorac Oncol; 2019 Aug; 14(8):e181-e183. PubMed ID: 31345345
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
    Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q
    Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
    Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C155-9. PubMed ID: 25450275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
    Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
    J Cancer Res Ther; 2016; 12(3):1127-1131. PubMed ID: 28054523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
    Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
    Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
    Ren YL; Sheng J; Zhou XY; Fang Y; Pan HM
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):152-153. PubMed ID: 30862147
    [No Abstract]   [Full Text] [Related]  

  • 17. New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.
    Zheng Y; Fang W; Liu X; Xu N
    Tumori; 2012; 98(4):e102-4. PubMed ID: 23052173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
    Zhou S; Hu X; Wang Y; Li J; Zhou L; Hao X; Liu Y; Shi Y
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):166-171. PubMed ID: 30311393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
    Liu Q; Wu L; Zhang S
    Tumori; 2021 Dec; 107(6):NP5-NP10. PubMed ID: 33896242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
    Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM
    Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.